Get our FREE Strategy & Transformation Templates. This is an exclusive promotion being run on LinkedIn.
  This is a partial preview. Full document is 29 slides. View large preview.
If you are logged in, your referral link [?] is automatically included below.
EMBED CODE (Copy and Paste)


DOCUMENT DESCRIPTION

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Pharma Disease Insight: Multiple Myeloma PowerPoint document

This document can be purchased as part of a discount bundle:

Pharma Disease Insight Oncology Bundle View Details
 

Pharma Disease Insight: Multiple Myeloma

Sold by BigPharma2000 (this author has 17 documents)

$99.00

ALL FEES INCLUDED
Add to Cart
  

This business document is categorized under the function(s): None specified.

It applies to .

File Type: PowerPoint (pptx)

File Size: 1.9 MB

Number of Slides: 29

Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.

Initial upload date (first version): Jun 8, 2017
Most recent version published: Jun 8, 2017

Ask the Author a Question

Must be logged in Click here to log in

Report

SELECT CUSTOMERS

Flevy has provided quality business documents to businesses and organizations of all sizes across the world—in over 60 countries. Below is just a very small sample of our customer base.

VIEW BY


Are you a business professional?
Join Flevy and sell your business documents.

Just as the mobile apps market has helped software developers earn sustainable, passive income, we hope Flevy will do the same for business professionals, like yourself. There's no reason to let your IP collect dust when it can be making you perpetual income.


CUSTOMERS ALSO BOUGHT THESE DOCUMENTS

What project are you working on?
Bain Presentations?   Growth-Share Matrix?   Sales?   Or something else.
Have a look at our holistic Business Toolkits. We have over 250+ toolkits covering a wide range of business topics.